The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

ClinicalTCCL Archive

NCI CTEP-Approved Trials for the Month of November

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase II

9598: A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients with BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease. National Institutes of Health; Estrada-Veras, Juvianee Ibrahim. (301) 594-2952

9653: Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder. University of California Davis Comprehensive Cancer Center P2C; Sadeghi, Sarmad. (323) 865-0553

9880: Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous Recombinant Human IL-15 (rhIL-15) in Adults with Refractory or Relapsed Acute Myelogenous Leukemia. University of Minnesota Medical Center-Fairview; Miller, Jeffrey Steven (612) 624-0123

NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma. NRG Oncology; Mehta, Minesh P. (410) 328-9629

NRG-HN002: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer. NRG Oncology; Yom, Sue Sun (415) 353-7410

Other Phases

A151315: An Analysis of Baseline Serum NTx and BAP as Independent Predictors of Overall Survival and Risk of SREs. Alliance for Clinical Trials in Oncology; Saylor, Philip James. (617) 643-1763

ECOG-E2197F-ECOG-ICSC: Tumor MicroEnvironment of Metastasis (TMEM) and MenaCalc: Validation as Prognostic and Predictive Markers. ECOG-ACRIN Cancer Research Group; Sparano, Joseph Anthony (718) 904-2555

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
By W. Kimryn Rathmell

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account